<DOC>
	<DOCNO>NCT01277289</DOCNO>
	<brief_summary>The aim study assessment efficacy Ery-Dex ( dexamethasone intra-erythrocyte ) versus placebo maintain patient steroid-dependent Crohn 's disease clinical remission throughout 12 month without oral steroid .</brief_summary>
	<brief_title>Intra-erythrocyte Dexamethasone Versus Placebo Patients With Steroid-dependent Crohn 's Disease</brief_title>
	<detailed_description>The medical treatment Crohn 's disease still unsatisfactory despite use large number drug steroid cause several side effect long-term treatment.Ery-Dex thanks peculiar way administration ( intra-erythrocyte encapsulation release low dos 1 month ) dramatically reduce side effect due steroid , dose dependent , provide alternative long-term glucocorticoid therapy .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>male female patient ; age &gt; 18 year patient steroiddependent CD clinical remission show relapse last 12 month treatment 10mg methylprednisone least patient willing able give write informed consent CD intestinal subocclusion , suspect abdominal abcess , active perianal disease CDAI &gt; 150 pt . already therapy immunosuppressant agent le 4 month pt . receive Infliximab ( antiTNF ) previous 3 month severe concomitant disease elective surgery already schedule start study chronic use alcohol ; drug addiction pregnant woman subject contraindication use steroid investigational treatment previous 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>dexamethasone</keyword>
	<keyword>ery-dex</keyword>
	<keyword>Chron 's disease</keyword>
	<keyword>CD</keyword>
</DOC>